FDA 2026 Compounded GLP-1 Rules: A Patient Action Guide

If you're on compounded semaglutide or tirzepatide, the regulatory ground has been moving under your feet since the 2024–2025 shortage list shifts. Here's what to do — practically — depending on where you are right now.

A 90-second background

The FDA permits compounding of a drug when the brand-name version is in shortage. Both semaglutide and tirzepatide spent much of 2023–2024 on the shortage list, which let 503A pharmacies (state-licensed) and 503B outsourcing facilities (FDA-registered) legally produce compounded versions at a fraction of the brand-name price.

When the FDA declared the shortages resolved, the legal basis for compounding narrowed sharply. The 2025–2026 picture:

• Brand-name shortages are intermittently resolved/unresolved depending on supply
• 503B facilities were told to wind down semaglutide compounding once the resolution stuck
• 503A pharmacies have more leeway when doing a legitimate personalized formulation for a specific patient — but the bar is higher now
• New FDA enforcement priorities are focused on operations that look industrial rather than personalized

This is fluid. By the time you read this, specifics may have shifted again. The principles below are stable; the dates aren't.

If you're currently on compounded GLP-1: do this

1. Confirm your pharmacy's registration. Ask your clinic: Is my prescription filled by a 503A pharmacy or a 503B facility, and is it currently in good FDA standing? Get a name. If they won't answer, that's the answer.
2. Stockpile responsibly, don't hoard. Refilling 30 days early is reasonable. Stockpiling 6 months of pens that may sit unused isn't — these are biologics with cold-chain requirements.
3. Ask about the personalization on your formulation. If it's plain semaglutide at standard concentration, you're closer to the enforcement spotlight. If there's a documented reason for the compound (e.g., a B12 combination, a different concentration for a specific medical reason), you're on firmer ground.
4. Have a brand-name fallback identified now. Know which clinic, which pharmacy, and what the cash price would be if compounded becomes unavailable next month. What Wegovy costs without insurance →
5. Confirm telehealth licensure. Your prescriber must be licensed in your state, full stop. Don't assume.

If you're considering starting compounded GLP-1: think harder

Compounded GLP-1 was 2024's killer value proposition: same molecule, fraction of the price. In 2026 the calculus is different:

• Supply risk is real — clinics have had to switch patients off mid-cycle
• Price gap is narrower — brand-name cash prices have dropped, some routes are under $400/mo
• An emerging oral pill changes the cost equation again: Wegovy oral pill →, Orforglipron →

A reasonable patient framework in 2026:

• Want lowest possible cost, willing to manage supply risk → compounded with a verified pharmacy
• Want stable supply, will pay more → brand name through insurance or cash-pay
• Want to wait → oral options are improving fast

Questions to ask any clinic right now

Bring these to any consult, brand-name or compounded:

1. "Who is the pharmacy filling my prescription, and are they currently in good FDA/state standing?"
2. "If compounded availability is interrupted, what's your transition plan for active patients?"
3. "Do you have a brand-name option in-network or via a partnered cash-pay program?"
4. "What's your refund policy if my prescription can't be filled?"
5. "Who handles side-effect questions between visits, and how fast do they respond?"

A clinic that can't answer the first four shouldn't be your clinic.

What's likely to happen next

Things to watch in mid-to-late 2026:

• Brand-name shortage redesignations can flip the compounding picture overnight
• New FDA enforcement actions against specific facilities (telegraphed publicly)
• The oral GLP-1 wave (Wegovy oral, orforglipron) creating new cash-pay tiers
• Insurance expansion for cardiovascular indications — a separate path that's been slowly opening

Find a clinic ready for either path

Browse LegitScript-verified clinics → — filter by whether they offer brand-name, compounded, or both, and check FDA-warning status on each Trust Score.

General information, not medical or legal advice. Compounded medication availability and regulation are evolving — confirm specifics with your clinician and pharmacy at the time of refill.